18 résultats avec le mot-clé: 'safety efficacy daclatasvir sofosbuvir hcv genotype infected patients'
Conclusion The sofosbuvir+daclatasvir combination is associated with a high rate of SVR12 in patients infected by genotype 1, with an optimal duration of 12 weeks in non-cirrhotic and
N/A
The first patient was a 59-year-old female infected with HCV genotype 2 receiving sofosbuvir and daclatasvir who stopped treatment at 18 days of administration due to adverse
N/A
Thirty-seven patients (90.2%) had a complete clinical response (defined by improvement of all the affected organs involved at baseline and no clinical relapse) after
N/A
For patients infected with HCV genotype 3, extending sofosbuvir–ribavirin treatment to 24 weeks resulted in substantially higher rates of response and lower rates of re- lapse
N/A
On remarquera qu’il y a deux arˆ etes de 2 vers 1 avec l’´ etiquette a, c’est donc ici que les triplets “(source, lettre, but)” ne s´ eparent pas les arˆ etes.. 4 et faire
N/A
Most patients (81%) received the sofosbu- vir/simeprevir combination without ribavirin for 12 weeks with a SVR of 93%. No significant difference in SVR12 rate was found between 12 or
N/A
In recent Phase 2 and 3 studies, the treatment combination of daclatasvir and sofosbuvir achieved a rate of SVR12 above 95% in genotype 1 patients without cirrhosis [8]; rates above
N/A
In Allen’s narrative, this disruption of collective narratives by Ephanie’s personal trauma serves to underline the distinction between the destructive white narratives that
N/A
Doctorandas: Aicha Assafi, Dina Laghmari, Halima Aaddi y Marta
N/A
In conclusion, for our Caucasian cohort predomin- antly infected with genotype-HCV 1, hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is
N/A
Les anévrysmes de l’aorte abdominale sont dans la très grande majorité des cas d’origine athéroscléreuse. Cependant, le développement de la formation anévrysmale est
N/A
Velocity profiles decrease when magnetic parameter M increases, but the profiles increase with M after a certain point for the assisting flow.. 1 Physical model and coordinate
N/A
Addis Ababa, 17 June 2010 (ECA) - The United Nations Economic Commission for Africa (ECA) has launched a network of community of experts and institutions involved in
N/A
Cite this article as: Prescription and efficacy of daclatasvir and sofosbuvir ± ribavirin for hepatitis C infection, includ- ing patient-reported outcomes, in routine practice in
N/A
Law itz reports receiving consulting fees from AbbVie, Achillion Pharmaceuticals, Idenix Pharmaceuticals, Janssen Pharmaceuticals, Novartis, Merck, Vertex Pharmaceuticals,
N/A
High Efficacy in Patients With Chronic Hepatitis C Virus (HCV) Genotype (GT)1b Infection Treatment With Elbasvir/Grazoprevir for 12 Weeks: An Integrated
N/A
Pour les spécialités SOVALDI ® (sofosbuvir), DAKLINZA ® (daclatasvir), HARVONI ® (sofosbuvir/ledipatasvir), VIEKIRAX ® (ombitasvir-paritaprévir-ritonavir), EXVIERA ®
N/A
لابقع ـسم اـهرفوت نكألماو ةحاعلما ةيع لمجاو ةيسمرلا تناماضلا همم يضوت لىا اضيم ة ارلا فد ماك كلا في ماــظن دــتو لــعفُت نم
N/A